The stock is on a 13-session winning streak, its longest ever, and is up 9.9% in November, putting it on pace for its best month since April 2020. Shares have advanced 17% over the past three months, reflecting renewed investor confidence. Wall Street is increasingly optimistic about the company's plans to address revenue gaps following patent expiration for its top-selling psoriasis drug, Stelara. Stronger sales guidance, rapid pipeline advances, and improving MedTech momentum amid a recovering sector are driving the positive performance.